Prof Ghosh presented data from the UNITI studies exploring ustekinumab in primary or secondary nonresponders to TNF agonists (UNITI-1) and conventional therapy failures (UNITI-2).
In this issue
Latest articles
All articles![](https://www.emjreviews.com/wp-content/uploads/2024/03/NCA-What-is-PEAL-Syndrome-Gast-940x564.png)
![](https://www.emjreviews.com/wp-content/uploads/2023/11/Is-Intestinal-Cell-Death-in-Necrotising-Enterocolitis-Assorted-and-Multifarious-940x564.png)
![](https://www.emjreviews.com/wp-content/uploads/2023/11/Gastro_CaseReport_SAPHO-Syndrome-in-Crohns-Disease-940x564.jpg)
![](https://www.emjreviews.com/wp-content/uploads/2023/11/Gideon-Hirschfield-940x564.png)
Prof Ghosh presented data from the UNITI studies exploring ustekinumab in primary or secondary nonresponders to TNF agonists (UNITI-1) and conventional therapy failures (UNITI-2).